A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

A KEIGHLEY deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

Several foreign drugmakers have announced debuts for their new drugs in the Chinese market since the beginning of 2025, as ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therapeutics (BCYC – Research Report). The associated price target ...

NDAQ:BCYC) Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones ...